Most Recent
Israeli drug company Neurim Pharmaceuticals has lost a bid to patent a mini version of its melatonin tablet Circadin for children, after a successful challenge by Australian drug maker Generic Partners.
A judge has found that Uniden infringed rival GME’s design patent for a handheld radio, derailing the company's plan for an Australian launch of two products.
Concrete repair company Vector Corrosion Technologies has lost its bid for ownership of a concrete treatment patent held by three former employees who jumped ship, with a court finding the trio invented the technology after leaving Vector.
An Australian fashion designer suing Katy Perry over the rights to use the Katy Perry trade mark in Australia is a "calculating and dishonest witness" whose "utterly dishonest" testimony should not be believed, counsel for the pop star said during closing submissions.
US pop star Katy Perry has been accused of using her “financial might” to “snuff out” the small business of an Australian fashion designer, as trial kicked off in a long-running intellectual property dispute over the rights to use the Katy Perry trade mark in Australia.
Pharmaceutical giants Merck Sharpe & Dohme and Pfizer have resolved a long-running intellectual property dispute over a 2015 patent owned by Pfizer for a pneumococcal vaccine.
US singer Katy Perry can withdraw an admission in a trade mark infringement case that licensing her brand to Target and Myer constituted use, with a judge finding the admission was “not consistent with current law”.
US singer Katy Perry is seeking to withdraw an admission that licensing her trade mark to Target and Myer constituted use, saying it was plainly “wrong” after the Full Federal Court held an owner who authorised use of a mark was not liable for direct infringement.
US singer Katy Perry has won a ruling shielding communications with lawyers from 2009 in a trade mark dispute with Australian fashion designer Katie Perry.
US chemical company Quaker Chemical is seeking special leave from the High Court to appeal a Full Court judgment that found its patents for quickly detecting high pressure fluid injection injuries on site were not novel because the company had disclosed them in public prior to applying for registration with IP Australia.